PNET
MCID: ISL001
MIFTS: 59

Islet Cell Tumor (PNET)

Categories: Cancer diseases, Endocrine diseases, Gastrointestinal diseases, Neuronal diseases, Rare diseases
Data Licensing
For inquiries, contact:

Aliases & Classifications for Islet Cell Tumor

MalaCards integrated aliases for Islet Cell Tumor:

Name: Islet Cell Tumor 11 19 53 14 16 71
Pancreatic Neuroendocrine Tumor 19 58 16 75
Neuroendocrine Tumor of Pancreas 19 58 5
Well-Differentiated Neuroendocrine Neoplasm of Pancreas 19 58
Well-Differentiated Pancreatic Neuroendocrine Neoplasm 19 58
Well-Differentiated Nen of Pancreas 19 58
Well-Differentiated Pancreatic Nen 19 58
Pancreatic Endocrine Tumor 19 75
Pancreatic Net 19 58
Pnet 19 58
Well Differentiated Pancreatic Endocrine Tumor 71
Malignant Neoplasm of Endocrine Pancreas 71
Malignant Tumour of Endocrine Pancreas 11
Malignant Pancreatic Endocrine Tumour 11
Malignant Tumor of Endocrine Pancreas 11
Malignant Pancreatic Endocrine Tumor 11
Pancreatic Neuroendocrine Neoplasm 19
Pancreatic Endocrine Carcinoma 71
Pancreatic Endocrine Neoplasm 11
Endocrine Pancreas Cancer 11
Islet Cell Neoplasm 11
Adenoma, Islet Cell 43
Islet Cell Tumour 11

Characteristics:


Inheritance:

Neuroendocrine Tumor of Pancreas: Autosomal dominant 58

Prevelance:

Neuroendocrine Tumor of Pancreas: 1-9/1000000 (United States, France, Europe) 1-9/100000 (Japan, Japan) 1-5/10000 (United States) 58

Age Of Onset:

Neuroendocrine Tumor of Pancreas: Adult 58

Age Of Death:

Neuroendocrine Tumor of Pancreas: adult,elderly 58

Classifications:

Orphanet: 58  
Rare gastroenterological diseases
Rare endocrine diseases


External Ids:

Disease Ontology 11 DOID:1799
MeSH 43 D007516
NCIt 49 C27031
SNOMED-CT 68 254611009 261713004
ICD10 31 C25.4 D13.7
ICD10 via Orphanet 32 E16.8
UMLS via Orphanet 72 C0242363
Orphanet 58 ORPHA97253
UMLS 71 C0242363 C0496784 C1328479 more

Summaries for Islet Cell Tumor

GARD: 19 A Pancreatic neuroendocrine tumor, also called an islet cell tumor, is a type of neuroendocrine tumor (NET) that typically arises in the pancreas. However in some cases, a pancreatic NET occurs outside of the pancreas. A NET arises from cells that produce hormones, so the tumor can also produce hormones. It may be benign (not cancerous) or malignant (cancerous). Pancreatic NETs are called either functional or nonfunctional. A functional pancreatic NET causes specific symptoms because it makes extra hormones, such as gastrin, insulin, or glucagon. Examples of types of functional pancreatic NETs include insulinomas, glucagonomas, gastrinomas, VIPomas, and somatostatinomas. Symptoms depend on the type of hormone being made. A nonfunctional pancreatic NET generally does not cause specific symptoms, but may eventually cause symptoms relating to its location and size as it grows or spreads. Most pancreatic NETs are not inherited and occur sporadically in people with no family history of NETs. However, about 10% are associated with a hereditary cancer or tumor syndrome such as multiple endocrine neoplasia type 1 (MEN1), which has autosomal dominant inheritance.

MalaCards based summary: Islet Cell Tumor, also known as pancreatic neuroendocrine tumor, is related to non-functioning pancreatic endocrine tumor and mahvash disease. An important gene associated with Islet Cell Tumor is BRCA2 (BRCA2 DNA Repair Associated), and among its related pathways/superpathways are GPCR downstream signalling and Class A/1 (Rhodopsin-like receptors). The drugs Doxorubicin and Cisplatin have been mentioned in the context of this disorder. Affiliated tissues include pancreatic islet cells, pancreas and pancreatic islet, and related phenotypes are homeostasis/metabolism and nervous system

Orphanet: 58 Pancreatic endocrine tumor, also known as pancreatic neuroendocrine tumor (PNET), describes a group of endocrine tumors originating in the pancreas that are usually indolent and benign, but may have the potential to be malignant. They can be functional, exhibiting a hormonal hypersecretion syndrome, but can be non-functional presenting with non-specific symptoms and include insulinoma, glucagonoma, VIPoma, somatostatinoma (SSoma), PPoma and Zollinger-Ellison syndrome (ZES, or gastrinoma) and other ectopic hormone producing tumors (such as GRFoma) (see these terms).

Disease Ontology: 11 A pancreatic cancer that is located in the pancreatic islet cells.

Wikipedia 75 Pancreatic endocrine tumor: Neuroendocrine tumors (NETs) are neoplasms that arise from cells of the endocrine (hormonal) and nervous... more...

Pancreatic neuroendocrine tumor: Pancreatic neuroendocrine tumours (PanNETs, PETs, or PNETs), often referred to as "islet cell tumours",... more...

Related Diseases for Islet Cell Tumor

Diseases related to Islet Cell Tumor via text searches within MalaCards or GeneCards Suite gene sharing:

(show top 50) (show all 716)
# Related Disease Score Top Affiliating Genes
1 non-functioning pancreatic endocrine tumor 32.7 SST PPY MEN1 GAST CHGA
2 mahvash disease 32.6 PPY MEN1 GCG
3 vipoma 32.0 VIP SST SCT PPY MEN1 GAST
4 ganglioneuroblastoma 31.9 VIP SYP CHGA
5 somatostatinoma 31.7 VIP SST PPY MEN1 INS GCG
6 pancreatic endocrine carcinoma 31.4 SYP SST SERPINA3 PTHLH PPY MEN1
7 insulinoma 31.4 SYP SST SCT MEN1 INS IGF2
8 hypoglycemia 31.2 SST SCT INS IGF2 IAPP GCG
9 diarrhea 31.1 SST SCT GAST CALCA
10 zollinger-ellison syndrome 30.9 SST SCT MEN1 GAST CHGA
11 hyperinsulinism 30.9 SST INS IGF2 IAPP GCG
12 hypercalcemia, infantile, 1 30.8 PTHLH CALCA
13 carcinoid tumors, intestinal 30.8 SYP SST MEN1 GAST CHGA
14 adenoma 30.8 SYP SST RET MEN1 CHGA
15 glucagonoma 30.8 VIP SST SCT GAST CHGA
16 acromegaly 30.7 VIP SST MEN1 INS IGF2
17 ectopic cushing syndrome 30.7 SYP SST CHGA CALCA
18 carcinoid syndrome 30.7 SYP SST CHGA CALCA
19 cystadenoma 30.6 SYP SERPINA3 CHGA
20 peptic ulcer disease 30.6 SST SCT PPY MEN1 INS GAST
21 insulin-like growth factor i 30.6 SST INS IGF2
22 gastroparesis 30.5 SST SCT GAST
23 teratoma 30.5 SYP SST INS GCG CHGA
24 pituitary adenoma 30.5 SST RET MEN1 CHGA
25 pancreatic serous cystadenoma 30.5 MEN1 CHGA
26 pernicious anemia 30.4 SST INS GAST CHGA
27 gastritis, familial giant hypertrophic 30.4 SST MEN1 GAST
28 retroperitoneal hemangiopericytoma 30.4 INS IGF2
29 nutritional deficiency disease 30.4 SERPINA3 SCT GAST
30 thyroiditis 30.4 RET INS CALCA
31 obstructive jaundice 30.4 SYP SST SERPINA3
32 merkel cell carcinoma 30.3 SYP SST CHGA
33 gastritis 30.3 SST SCT GAST CHGA
34 multiple endocrine neoplasia, type iia 30.3 RET MEN1 CALCA
35 hyperinsulinemic hypoglycemia, familial, 2 30.3 SST SCT INS IGF2 GAST CHGA
36 large cell neuroendocrine carcinoma 30.3 SYP SST MEN1 CHGA
37 lipomatosis 30.3 MIR483 MEN1 INS
38 hyperparathyroidism 30.3 SCT RET PTHLH MEN1 GAST CHGA
39 pheochromocytoma 30.3 VIP SYP SST RET MEN1 IGF2
40 lung oat cell carcinoma 30.3 SYP CHGA
41 tuberous sclerosis 30.3 SYP SST INS CHGA
42 neurofibromatosis, type i 30.3 SST RET MEN1 BRCA2
43 hypoglycemic coma 30.3 INS IGF2 GCG
44 suppression of tumorigenicity 12 30.3 SYP SERPINA3 CHGA
45 leptin deficiency or dysfunction 30.3 PPY PCSK1 INS IAPP GCG
46 short bowel syndrome 30.3 VIP SST GCG GAST
47 irritable bowel syndrome 30.3 VIP SST GCG CHGA
48 colonic benign neoplasm 30.3 SERPINA3 PALB2 INS GAST
49 gastrointestinal stromal tumor 30.3 SYP SST SERPINA3 RET MEN1 IGF2
50 pancreatic acinar cell adenocarcinoma 30.2 SYP SERPINA3 CHGA BRCA2

Graphical network of the top 20 diseases related to Islet Cell Tumor:



Diseases related to Islet Cell Tumor

Symptoms & Phenotypes for Islet Cell Tumor

MGI Mouse Phenotypes related to Islet Cell Tumor:

45
# Description MGI Source Accession Score Top Affiliating Genes
1 homeostasis/metabolism MP:0005376 10.36 BRCA2 CALCA CHGA GAST GCG IAPP
2 nervous system MP:0003631 10.25 BRCA2 CALCA CHGA IGF2 INS MEN1
3 growth/size/body region MP:0005378 10.18 BRCA2 CHGA GCG IAPP IGF2 INS
4 normal MP:0002873 10.11 BRCA2 CALCA INS MEN1 PTHLH RET
5 endocrine/exocrine gland MP:0005379 10.06 BRCA2 CHGA GAST GCG IGF2 INS
6 neoplasm MP:0002006 10.02 BRCA2 CALCA GAST MEN1 PALB2 PTHLH
7 behavior/neurological MP:0005386 10 BRCA2 CALCA IGF2 INS MEN1 PCSK1
8 digestive/alimentary MP:0005381 9.96 BRCA2 GAST GCG IGF2 INS MEN1
9 immune system MP:0005387 9.73 BRCA2 GAST IAPP IGF2 INS MEN1
10 mortality/aging MP:0010768 9.47 BRCA2 CALCA CHGA GAST GCG IGF2

Drugs & Therapeutics for Islet Cell Tumor

Drugs for Islet Cell Tumor (from DrugBank, HMDB, Dgidb, PharmGKB, IUPHAR, NovoSeek, BitterDB):

(show top 50) (show all 142)
# Name Status Phase Clinical Trials Cas Number PubChem Id
1
Doxorubicin Approved, Investigational Phase 2, Phase 3 23214-92-8 31703
2
Cisplatin Approved Phase 3 15663-27-1 2767 5702198 441203
3
Carboplatin Approved Phase 2, Phase 3 41575-94-4 10339178 38904
4
Cyclophosphamide Approved, Investigational Phase 3 50-18-0, 6055-19-2 2907
5
Vincristine Approved, Investigational Phase 3 2068-78-2, 57-22-7 5978
6
Vinblastine Approved Phase 2, Phase 3 865-21-4 241903 13342
7
Etoposide Approved Phase 3 33419-42-0 36462
8
Lenograstim Approved, Investigational Phase 3 135968-09-1
9
Thiotepa Approved, Investigational Phase 3 52-24-4 5453
10
Methotrexate Approved Phase 3 1959-05-2, 59-05-2 4112 126941
11
Somatostatin Approved, Investigational Phase 3 38916-34-6, 51110-01-1 53481605 16129706
12
Levoleucovorin Approved, Experimental, Investigational Phase 2, Phase 3 68538-85-2, 58-05-9, 73951-54-9 149436 6006
13
Fluorouracil Approved Phase 2, Phase 3 51-21-8 3385
14
Bevacizumab Approved, Investigational Phase 2, Phase 3 216974-75-3 135329020
15
Oxaliplatin Approved, Investigational Phase 2, Phase 3 61825-94-3 43805 11947679 6857599
16
Sunitinib Approved, Investigational Phase 3 557795-19-4 5329102
17
Lanreotide Approved Phase 2, Phase 3 108736-35-2 71349 6918011
18
Vitamin A Approved, Nutraceutical, Vet_approved Phase 3 2052-63-3, 22737-97-9, 22737-96-8, 68-26-8 9904001 9947823 5280382 445354
19
Isotretinoin Approved, Investigational, Nutraceutical Phase 3 302-79-4, 4759-48-2 5538 444795 5282379
20
Folic acid Approved, Nutraceutical, Vet_approved Phase 2, Phase 3 59-30-3 6037
21 Pancreatic Polypeptide Investigational Phase 2, Phase 3 59763-91-6
22 Liposomal doxorubicin Phase 2, Phase 3
23 Antineoplastic Agents, Alkylating Phase 3
24 Alkylating Agents Phase 3
25 Antimetabolites Phase 3
26 Retinol palmitate Phase 3
27 Calcium, Dietary Phase 3
28 Adjuvants, Immunologic Phase 3
29 Tubulin Modulators Phase 3
30 Antimitotic Agents Phase 3
31 Antirheumatic Agents Phase 3
32
Etoposide phosphate Phase 3 16760419
33 Dermatologic Agents Phase 3
34 Folic Acid Antagonists Phase 3
35 Keratolytic Agents Phase 3
36 Hormones Phase 3
37 Hormone Antagonists Phase 3
38 Protein Kinase Inhibitors Phase 3
39 Micronutrients Phase 2, Phase 3
40 Folate Phase 2, Phase 3
41 Antidotes Phase 2, Phase 3
42 Protective Agents Phase 2, Phase 3
43 Vitamins Phase 2, Phase 3
44 Trace Elements Phase 2, Phase 3
45 Vitamin B9 Phase 2, Phase 3
46 Vitamin B Complex Phase 2, Phase 3
47 Antineoplastic Agents, Immunological Phase 2, Phase 3
48 Angiogenesis Inhibitors Phase 3
49
Calcium Nutraceutical Phase 3 7440-70-2 271
50
Tegafur Approved, Investigational Phase 2 17902-23-7 5386

Interventional clinical trials:

(show top 50) (show all 142)
# Name Status NCT ID Phase Drugs
1 Clinical Effectiveness of Serum Chromogranin A (CgA) Levels on Diagnostic Relevance, Response After Surgical Resection and Recurrence of Pancreatic Endocrine Tumors (PET) Unknown status NCT02759718 Phase 4
2 A SINGLE-ARM OPEN-LABEL INTERNATIONAL MULTI-CENTER STUDY OF THE EFFICACY AND SAFETY OF SUNITINIB MALATE (SU011248, SUTENT (REGISTERED)) IN PATIENTS WITH PROGRESSIVE ADVANCED METASTATIC WELL-DIFFERENTIATED UNRESECTABLE PANCREATIC NEUROENDOCRINE TUMORS Completed NCT01525550 Phase 4 sunitinib
3 Phase IV, Open-label, Multi-center, Single-arm Study of the Safety and Efficacy of Everolimus (Afinitor) in Adult Patients With Local Advanced or Metastatic, Well Differentiated Progressive Pancreatic Neuroendocrine Tumors (pNET) in China. Active, not recruiting NCT02842749 Phase 4 everolimus
4 A Randomized Double-blind Phase III Study of RAD001 10 mg/d Plus Best Supportive Care Versus Placebo Plus Best Supportive Care in the Treatment of Patients With Advanced Pancreatic Neuroendocrine Tumor (NET) Completed NCT00510068 Phase 3 Everolimus;Everolimus Placebo
5 Open Label Extension Study of Lanreotide Autogel 120 mg in Patients With Non-functioning Entero-pancreatic Endocrine Tumour Completed NCT00842348 Phase 3 lanreotide (Autogel formulation)
6 Randomized, Double-Blinded Phase III Study of Cabozantinib Versus Placebo in Patients With Advanced Neuroendocrine Tumors After Progression on Prior Therapy (CABINET) Recruiting NCT03375320 Phase 3 Cabozantinib S-malate
7 AN INTERNATIONAL PROSPECTIVE TRIAL ON MEDULLOBLASTOMA (MB) IN CHILDREN OLDER THAN 3 TO 5 YEARS WITH WNT BIOLOGICAL PROFILE (PNET 5 MB - LR and PNET 5 MB - WNT-HR), AVERAGE-RISK BIOLOGICAL PROFILE (PNET 5 MB -SR), OR TP53 MUTATION, AND REGISTRY FOR MB OCCURRING IN THE CONTEXT OF GENETIC PREDISPOSITION Active, not recruiting NCT02066220 Phase 2, Phase 3 Reduced-intensity maintenance chemotherapy;Maintenance chemotherapy;Induction Chemotherapy;Vinblastin Maintenance
8 A Phase III Randomized Trial for the Treatment of Newly Diagnosed Supratentorial PNET and High Risk Medulloblastoma in Children <36 Months Old With Intensive Induction Chemotherapy With Methotrexate Followed by Consolidation With Stem Cell Rescue Versus the Same Therapy Without Methotrexate Active, not recruiting NCT00336024 Phase 3 etoposide;cyclophosphamide;cisplatin;carboplatin;thiotepa;methotrexate;leucovorin calcium;vincristine sulfate
9 Efficacy of Carboplatin Administered Concomitantly With Radiation and Isotretinoin as a Pro-Apoptotic Agent in Other Than Average Risk Medulloblastoma/PNET Patients Active, not recruiting NCT00392327 Phase 3 Carboplatin;Cisplatin;Cyclophosphamide;Isotretinoin;Vincristine Sulfate
10 Non-functioning Pancreatic Neuroendocrine Tumors (NF-pNETs) in Multiple Endocrine Neoplasia Type 1 (MEN1) Treated With Somatostatin Analogs (SA) Versus NO Treatment - a Prospective, Randomized, Controlled Multicenter Study Not yet recruiting NCT02705651 Phase 3 Somatostatin-Analog
11 A Pilot Study of FOLFOX in Combination With Bevacizumab in Patients With Advanced Neuroendocrine Tumors Terminated NCT00227617 Phase 2, Phase 3 5-fluorouracil;leucovorin;oxaliplatin
12 A Phase III Randomized, Double-Blind Study Of Sunitinib (SU011248, SUTENT) Versus Placebo In Patients With Progressive Advanced/Metastatic Well-Differentiated Pancreatic Islet Cell Tumors Terminated NCT00428597 Phase 3 sunitinib malate;Placebo
13 A EUROPEAN, MULTICENTRE, PHASE II/III RANDOMISED DOUBLE-BLIND, PLACEBO CONTROLLED STUDY EVALUATING LANREOTIDE AS MAINTENANCE THERAPY IN PATIENTS WITH NON-RESECTABLE DUODENO-PANCREATIC NEUROENDOCRINE TUMOURS AFTER FIRST-LINE TREATMENT Terminated NCT02288377 Phase 2, Phase 3 lanreotide;Placebo
14 68Ga-DOTATATE PET Scan Imaging in Patients With Neuroendocrine Tumors Unknown status NCT02038738 Phase 1, Phase 2 68Ga-DOTATATE will be given in tracer doses and injected intravenously to image tumors by Positron Emission Tomography.
15 A Phase II Randomized,Controlled,Open Label,Multicentre Study of Tegafur Combined With Temozolomide Versus Tegafur Combined With Temozolomide and Thalidomide in Subjects With Advanced Pancreatic Neuroendocrine Tumor Unknown status NCT03204019 Phase 2 Tegafur and Temozolomide;Tegafur and Temozolomide combined with Thalidomide
16 Treatment Protocol for High-Risk PNET Brain Tumors in Children With Surgery, Sequential Chemotherapy, Conventional and High-Dose With Peripheral Blood Stem Cell Transplantation and Radiation Therapy Unknown status NCT00180791 Phase 2 Etoposide, carboplatin, melphalan, cisplatin, thiotepa
17 A Phase II Study of Isolated Hepatic Perfusion (IHP) With Melphalan for Metastatic Unresectable Cancers of the Liver Completed NCT00019786 Phase 2 isolated perfusion;melphalan
18 A Randomised Phase II Study Comparing Capecitabine Plus Streptozocin With or Without Cisplatin Chemotherapy as Treatment for Unresectable or Metastatic Neuroendocrine Tumors Completed NCT00602082 Phase 2 capecitabine;cisplatin;streptozocin
19 A Phase II Clinical and Biologic Study of AMG 706 and Octreotide in Patients With Low-Grade Neuroendocrine Tumors Completed NCT00427349 Phase 2 AMG 706;octreotide
20 Study of First-Line Therapy Comprising Leucovorin Calcium, Fluorouracil, and Irinotecan (FOLFIRI) in Patients With Progressive Locally Advanced or Metastatic Duodenal-Pancreatic Endocrine Tumors Completed NCT00416767 Phase 2 fluorouracil;irinotecan hydrochloride;leucovorin calcium
21 Phase II Study of Sunitinib Malate Following Hepatic Artery Embolization for Metastatic Gastrointestinal Neuroendocrine Tumors Completed NCT00434109 Phase 2 Sunitinib malate
22 Phase II Trial Of Thalidomide In Patients With Low Grade Neuroendocrine Tumors (Carcinoid and Islet Cell Cancers) Completed NCT00027638 Phase 2 thalidomide
23 Phase II Study of PS-341 in Metastatic Neuroendocrine Tumors Completed NCT00017199 Phase 2 bortezomib
24 Randomized Phase II Study of Everolimus Alone Versus Everolimus Plus Bevacizumab in Patients With Locally Advanced or Metastatic Pancreatic Neuroendocrine Tumors Completed NCT01229943 Phase 2 Everolimus;Octreotide Acetate
25 A Phase II Study of LEE011 (Ribociclib) in Patients With Advanced Neuroendocrine Tumors of Foregut Origin Completed NCT02420691 Phase 2 Ribociclib
26 Phase II Study to Evaluate Efficacy of Rechallenge With Sunitinib in Patients With Metastatic Pancreatic Neuroendocrine Tumor (pNETs) Well Differentiated G1/2 Advanced or Metastatic Who Previously Failed to Sunitinib. Completed NCT02713763 Phase 2 Sunitinib
27 Temozolomide or Dacarbazine-based Chemotherapy Plus Endostatin in Advanced Pancreatic Neuroendocrine Tumor Completed NCT01845675 Phase 2 temozolomide or dacarbazine-based chemotherapy, endostatin
28 An Open Label, Stratified, Single-arm Phase II Study of Everolimus in Patients With Advanced Pancreatic Neuroendocrine Tumor (NET) After Failure of Cytotoxic Chemotherapy Completed NCT00363051 Phase 2 Everolimus 10 mg;Octreotide Depot
29 Phase I/II Study of RAD001 in Combination With Temozolomide in Patients With Advanced Pancreatic Neuroendocrine Tumors Completed NCT00576680 Phase 1, Phase 2 RAD001;Temozolomide
30 A Multi-Institutional, Phase II Open-Label Study of AMG 479 in Advanced Carcinoid and Pancreatic Neuroendocrine Tumors Completed NCT01024387 Phase 2 AMG 479
31 Phase II Study of Ibrutinib in Advanced Carcinoid and Pancreatic Neuroendocrine Tumors Completed NCT02575300 Phase 2 Ibrutinib
32 Feasibility of Using Concurrent Carboplatin and Reduced Dose Craniospinal Radiation (24Gy) for Metastatic Medulloblastoma, High-Risk Supratentorial PNET and Metastatic PNET Completed NCT01542736 Phase 2 Carboplatin;Vincristine
33 Phase II Multicenter, Open-label, Clinical and Pharmacokinetic Study of Zalypsis® (PM00104) in Patients With Unresectable Locally Advanced and/or Metastatic Ewing Family of Tumors (EFT) Progressing After at Least One Prior Line of Chemotherapy Completed NCT01222767 Phase 2 Zalypsis
34 A Phase I/II Study of Local Field Irradiation and Temozolomide Followed by Continuous Infusion Plerixafor as an Upfront Therapy for Newly Diagnosed Glioblastoma GBM Completed NCT01977677 Phase 1, Phase 2 temozolomide;plerixafor
35 A Five-Tier, Phase 2 Open-Label Study of IMC-A12 Administered as a Single Agent Every 2 Weeks in Patients With Previously-Treated, Advanced or Metastatic Soft Tissue and Ewing's Sarcoma/PNET Completed NCT00668148 Phase 2
36 A Multicenter, Two Stage, Phase II Study, Evaluating the Efficacy of Oral BEZ235 Plus Best Supportive Care (BSC) Versus Placebo Plus BSC in the Treatment of Patients With Advanced Pancreatic Neuroendocrine Tumors (pNET) After Failure of mTOR Inhibitor Therapy. Completed NCT01658436 Phase 2 BEZ235 (Stage 1)
37 A Phase I/II Study of the Combination of Temozolomide and Pazopanib in Advanced Pancreatic Neuroendocrine Tumors (PNET) Completed NCT01465659 Phase 1, Phase 2 temozolomide;pazopanib hydrochloride
38 A Ph 2 Study to Investigate the Safety and Activity of Fosbretabulin Tromethamine (CA4P) in the Treatment of Well-Differentiated, Low-to-Intermediate-Grade Unresectable, Recurrent or Metastatic PNET or GI-NET Neuroendocrine Tumors/Carcinoid With Elevated Biomarkers Completed NCT02132468 Phase 2 fosbretabulin tromethamine
39 A Phase II Trial of Preradiation Multiagent Chemotherapy for Adults With "Poor Risk" Medulloblastoma, PNET, and Disseminated Ependymoma Completed NCT00003309 Phase 2 cisplatin;cyclophosphamide;etoposide;vincristine sulfate
40 A Phase II Study of R115777 (Zarnestra) (NSC # 702818, IND# 58,359) in Children With Recurrent or Progressive: High Grade Glioma, Medulloblastoma/PNET or Brainstem Glioma Completed NCT00070525 Phase 2 tipifarnib
41 A Phase II Trial to Assess the Activity and Safety of Palbociclib in Patients With Well and Moderately Differentiated Metastatic Pancreatic Neuroendocrine Tumors (pNET) Completed NCT02806648 Phase 2 Palbociclib
42 Dose Intensive Chemotherapy for Patients Greater Than or Equal To 10 Years of Age With Newly Diagnosed High Stage Medulloblastoma, Supratentorial Primitive Neuroectodermal Tumors (PNET) and Ependymoma: A Feasibility Study of an Intensive Induction Chemotherapy Regimen Followed by Standard Irradiation Completed NCT00006258 Phase 2 cisplatin;cyclophosphamide;etoposide;methotrexate;vincristine sulfate
43 A Phase II Study Of Intravenous DX-8951f (EXATECAN MESYLATE) Administered Daily For Five Days Every Three Weeks To Pediatric And Young Adult Patients With Ewing's Sarcoma (ES), Primitive Neuroectodermal Tumor (PNET), Or Desmoplastic Small Round Cell Tumor (DSRCT) Completed NCT00055952 Phase 2 exatecan mesylate
44 CAMP 013:- Tandem Thiotepa Regimen For Selected Malignant Gliomas:1) Primary Or Recurrent Glioblastoma Multiforme (GBM); and 2) Recurrent Anaplastic Astrocytomas (AA), Oligodendrogliomas (O), Oligoastrocytomas (OA), Ependymomas And Primitive Neuroectodermal Tumors (PNET) That Have Either Progressed After Primary Therapy Or Are Refractory To Standard Chemotherapy Completed NCT00008008 Phase 2 cyclophosphamide;thiotepa
45 Treatment of Newly Diagnosed Medulloblastoma and Supratentorial PNET in Patients At Least 3 Years With a Phase II Topotecan Window (High-Risk Patients Only), Risk-Adapted Radiation Therapy, and Dose-Intensive Chemotherapy With Peripheral Blood Stem Cell Support Completed NCT00003211 Phase 2 amifostine trihydrate;cisplatin;cyclophosphamide;vincristine sulfate
46 Temozolomide With Irinotecan Versus Temozolomide, Irinotecan Plus Bevacizumab (NSC# 704865) for Recurrent/Refractory Medulloblastoma/CNS PNET of Childhood, a COG Randomized Phase II Screening Trial Completed NCT01217437 Phase 2 Irinotecan Hydrochloride;Temozolomide
47 Rollover for Study OX4218s, A P2 Study to Investigate Safety and Activity of Fosbretabulin Tromethamine in the Treatment of Well-Differentiated, Low-to-Intermediate-Grade Unresectable, Recurrent or Metastatic PNET or GI-NET With Elevated Biomarkers Completed NCT02279602 Phase 2 fosbretabulin
48 A Phase II Study to Assess the Activity and Safety of TH-302 in Combination With Sunitinib in Treatment-naïve Patients With Well- and Moderately-differentiated Metastatic Pancreatic Neuroendocrine Tumours (pNET) Completed NCT02402062 Phase 2 TH-302 + Sunitinib
49 Evaluation of Treatment With Interferon, Octreotide, or Their Combination in Patients With Zollinger-Ellison Syndrome and Progressive Metastatic Non-B Islet Cell Neoplasm Completed NCT00001228 Phase 2 Interferon
50 Evaluation of Chemotherapy With Streptozotocin Combined With 5-Fluorouracil and Adriamycin in Patients With Zollinger-Ellison Syndrome and Metastatic Non-Beta-Islet Cell Neoplasm Completed NCT00001165 Phase 2 combined chemotherapy with streptozotocin, 5-fluorouracil, and doxorubicin

Search NIH Clinical Center for Islet Cell Tumor

Inferred drug relations via UMLS 71 / NDF-RT 50 :


Dacarbazine

Cochrane evidence based reviews: adenoma, islet cell

Genetic Tests for Islet Cell Tumor

Anatomical Context for Islet Cell Tumor

Organs/tissues related to Islet Cell Tumor:

FMA: Pancreatic Islet Cells
MalaCards : Pancreas, Pancreatic Islet, Lung, Lymph Node, Brain, Liver, Bone Marrow

Publications for Islet Cell Tumor

Articles related to Islet Cell Tumor:

(show top 50) (show all 4946)
# Title Authors PMID Year
1
Nonsense-mediated mRNA decay: terminating erroneous gene expression. 5
15145354 2004
2
Use of the tyrosine kinase inhibitor sunitinib in a patient with von Hippel-Lindau disease: targeting angiogenic factors in pheochromocytoma and other von Hippel-Lindau disease-related tumors. 53 62
19017755 2009
3
Insulin and somatostatin releasing islet cell tumor caused hypoglycemia. 53 62
11334393 2001
4
Islet cell tumor in von Hippel-Lindau disease. 53 62
9617866 1998
5
Multihormone-producing islet cell tumor of the pancreas associated with somatostatin-immunoreactive amyloid: immunohistochemical and immunoelectron microscopic studies. 53 62
9500779 1998
6
Pancreatic islet cell tumor producing vasoactive intestinal polypeptide and calcitonin. 53 62
9494586 1997
7
Absence of RET proto-oncogene mutations in a father and son with pheochromocytoma and pancreatic islet cell tumor. 53 62
9179691 1997
8
The glucagonoma syndrome. Clinical and pathologic features in 21 patients. 53 62
8606627 1996
9
PTHrP-mediated hypercalcemia in a calcitonin-producing islet cell tumor. 53 62
15251589 1995
10
Comparison of chromogranin A and pancreastatin levels in plasma of patients with pancreatic islet cell tumor. 53 62
7630318 1995
11
Production and secretion of chromogranin A and pancreastatin by the human pancreatic carcinoma cell line QGP-1N on stimulation with carbachol. 53 62
7800852 1994
12
Pancreastatin producing cell line from human pancreatic islet cell tumor. 53 62
2159299 1990
13
Endoscopic ultrasound-guided radiofrequency ablation of premalignant pancreatic-cystic neoplasms and neuroendocrine tumors: prospective study. 62
36170679 2022
14
Management of a Patient With Metastatic Gastrointestinal Neuroendocrine Tumor and Meningioma Submitted to Peptide Receptor Radionuclide Therapy With 177 Lu-DOTATATE. 62
35695716 2022
15
Comparison Between Sporadic and Multiple Endocrine Neoplasia Type 1-Associated Insulinoma. 62
35752874 2022
16
Metastatic Grade 3 Neuroendocrine Tumor in Multiple Endocrine Neoplasia Type 1 Expressing Somatostatin Receptors. 62
36111275 2022
17
miR-3156-5p is downregulated in serum of MEN1 patients and regulates expression of MORF4L2. 62
35900839 2022
18
Molecular classification and outcome of children with rare CNS embryonal tumors: results from St. Jude Children's Research Hospital including the multi-center SJYC07 and SJMB03 clinical trials. 62
35982322 2022
19
Renal primitive neuroectodermal tumor. The first case series from Syria. 62
36268368 2022
20
A phase II study of sapanisertib (TAK-228) a mTORC1/2 inhibitor in rapalog-resistant advanced pancreatic neuroendocrine tumors (PNET): ECOG-ACRIN EA2161. 62
36264382 2022
21
Association between fibrosis markers and kidney function following peptide receptor radionuclide therapy in patients with neuroendocrine tumours. 62
36129406 2022
22
The real-world selection of first-line systemic therapy regimen for metastatic gastroenteropancreatic neuroendocrine neoplasm in Japan. 62
36266484 2022
23
Differential Detection of Hepatic Metastases on 68Ga-DOTATATE PET/CT and 177Lu-DOTATATE SPECT/CT. 62
36240803 2022
24
An analysis of the effectiveness of stapler closure combined with a titanium clip in distal pancreatectomy. 62
35138460 2022
25
Large low-grade cystic pancreatic neuroendocrine neoplasm. 62
33090626 2022
26
Age in combination with gender is a valuable parameter in differential diagnosis of solid pseudopapillary tumors and pancreatic neuroendocrine neoplasm. 62
36271376 2022
27
Frequency of Adrenal Insufficiency in Patients With Hypoglycemia in an Emergency Department: A Cross-sectional Study. 62
36042975 2022
28
Diffuse Involvement of Pancreas is not Always Autoimmune Pancreatitis. 62
35279380 2022
29
A case of erythema multiforme-like rash induced by everolimus in a patient with a pancreatic neuroendocrine tumor. 62
36264476 2022
30
Successful Surgical Treatment of a Recurrent Pelvic Solitary Fibrous Tumor of Uterine Origin Accompanied by Doege-Potter Syndrome: A Case Report. 62
36227783 2022
31
Baicalein activates 5' adenosine monophosphate-activated protein kinase, inhibits the mammalian target of rapamycin, and exhibits antiproliferative effects in pancreatic neuroendocrine tumors in vitro and in vivo. 62
36207198 2022
32
Glucoregulatory factors in canine hepatocellular carcinoma and leiomyosarcoma with non-islet cell tumour hypoglycaemia. 62
36209617 2022
33
"Neuroendocrine Tumor Grade 3 (NET G3)" of the Uterine Cervix: A Report of 2 Cases. 62
34570015 2022
34
Diffuse Involvement of Pancreas Should Raise Suspicion of Mahvash Disease, an Autosomal Recessive Pancreatic Neuroendocrine Tumor Syndrome. 62
36075823 2022
35
Authors' Reply to "Diffuse Involvement of Pancreas Should Raise Suspicion of Mahvash Disease, an Autosomal Recessive Pancreatic Neuroendocrine Tumor Syndrome". 62
36180326 2022
36
Venous invasion and lymphatic invasion are correlated with the postoperative prognosis of pancreatic neuroendocrine neoplasm. 62
36123176 2022
37
Surgical outcomes of gastro-entero-pancreatic neuroendocrine tumors G3 versus neuroendocrine carcinoma. 62
35616186 2022
38
Long-term Survival in a Child with Malignant Insulinoma After Liver Transplantation. 62
36047503 2022
39
Therapeutic experience of a pancreatic mixed serous neuroendocrine neoplasm invading peripancreatic vessels: A case report. 62
36107509 2022
40
Insulinoma: a quarter century of dietary control. 62
36137190 2022
41
Distinguishing pancreatic solid serous cystadenomas from nonfunctional pancreatic neuroendocrine tumors by computed tomography: A propensity score analysis. 62
36123910 2022
42
Endoscopic ultrasound-guided radiofrequency ablation of premalignant pancreatic-cystic neoplasms and neuroendocrine tumors: prospective study. 62
36165056 2022
43
Long-term Outcomes of Parenchyma-sparing and Oncologic Resections in Patients With Nonfunctional Pancreatic Neuroendocrine Tumors <3 cm in a Large Multicenter Cohort. 62
35758433 2022
44
Prognostic role of hERG1 Potassium Channels in Neuroendocrine Tumours of the Ileum and Pancreas. 62
36142530 2022
45
Development and validation of nomogram to predict lymph node metastasis preoperatively in patients with pancreatic neuroendocrine tumor. 62
36127226 2022
46
Misdiagnosis of pancreatic metastasis from renal cell carcinoma: A case report. 62
36157676 2022
47
Primary and metastatic primitive neuroectodermal tumor of the heart: A systematic review. 62
35306869 2022
48
Molecular pathological insights reveal a high number of unfavorable risk patients among children treated for medulloblastoma and CNS-PNET in Oslo 2005-2017. 62
35570402 2022
49
Comparison of the mutational profiles of neuroendocrine breast tumours, invasive ductal carcinomas and pancreatic neuroendocrine carcinomas. 62
36085291 2022
50
Early Detection of Relapse by ctDNA Sequencing in a Patient with Metastatic Thymic Tumor and MEN1 Mosaicism. 62
35904487 2022

Variations for Islet Cell Tumor

ClinVar genetic disease variations for Islet Cell Tumor:

5
# Gene Name Type Significance ClinVarId dbSNP ID Position
1 PALB2 NM_024675.4(PALB2):c.778C>T (p.Gln260Ter) SNV Pathogenic
560018 rs1555461627 GRCh37: 16:23647089-23647089
GRCh38: 16:23635768-23635768
2 BRCA2 NM_000059.4(BRCA2):c.994dup (p.Ile332fs) DUP Pathogenic
52925 rs80359777 GRCh37: 13:32906602-32906603
GRCh38: 13:32332465-32332466

Cosmic variations for Islet Cell Tumor:

8 (show top 50) (show all 176)
# Cosmic Mut ID Gene Symbol COSMIC Disease Classification
(Primary site, Site subtype, Primary histology, Histology subtype)
Mutation CDS Mutation AA GRCh38 Location Conf
1 COSM91859716 KRAS pancreas,NS,carcinoid-endocrine tumour,islet cell c.35G>A p.G12D 12:25245350-25245350 23
2 COSM134990112 KRAS pancreas,NS,carcinoid-endocrine tumour,islet cell c.35G>A p.G12D 12:25245350-25245350 23
3 COSM134614922 KRAS pancreas,NS,carcinoid-endocrine tumour,islet cell c.35G>A p.G12D 12:25245350-25245350 23
4 COSM87804005 KRAS pancreas,NS,carcinoid-endocrine tumour,islet cell c.35G>A p.G12D 12:25245350-25245350 23
5 COSM102811183 FGFR3 pancreas,NS,carcinoid-endocrine tumour,islet cell c.931-1099G>A p.? 4:1803725-1803725 23
6 COSM90925530 FGFR3 pancreas,NS,carcinoid-endocrine tumour,islet cell c.1082-605G>A p.? 4:1803725-1803725 23
7 COSM115719804 FGFR3 pancreas,NS,carcinoid-endocrine tumour,islet cell c.964G>A p.E322K 4:1803725-1803725 23
8 COSM91818291 FGFR3 pancreas,NS,carcinoid-endocrine tumour,islet cell c.931-1099G>A p.? 4:1803725-1803725 23
9 COSM142960323 FGFR3 pancreas,NS,carcinoid-endocrine tumour,islet cell c.*20G>A p.? 4:1803725-1803725 23
10 COSM107639729 FGFR3 pancreas,NS,carcinoid-endocrine tumour,islet cell c.964G>A p.E322K 4:1803725-1803725 23
11 COSM144102592 TP53 pancreas,NS,carcinoid-endocrine tumour,insulinoma c.340C>A p.R114S 17:7673803-7673803 18
12 COSM144031768 TP53 pancreas,NS,carcinoid-endocrine tumour,insulinoma c.784C>A p.R262S 17:7673803-7673803 18
13 COSM144327027 TP53 pancreas,NS,carcinoid-endocrine tumour,insulinoma c.700C>A p.R234S 17:7673803-7673803 18
14 COSM111779193 TP53 pancreas,NS,carcinoid-endocrine tumour,insulinoma c.817C>A p.R273S 17:7673803-7673803 18
15 COSM93204208 TP53 pancreas,NS,carcinoid-endocrine tumour,insulinoma c.817C>A p.R273S 17:7673803-7673803 18
16 COSM105643083 TP53 pancreas,NS,carcinoid-endocrine tumour,insulinoma c.782+378C>A p.? 17:7673803-7673803 18
17 COSM142852695 TP53 pancreas,NS,carcinoid-endocrine tumour,insulinoma c.817C>A p.R273S 17:7673803-7673803 18
18 COSM122754120 TP53 pancreas,NS,carcinoid-endocrine tumour,insulinoma c.421C>A p.R141S 17:7673803-7673803 18
19 COSM121897932 TP53 pancreas,NS,carcinoid-endocrine tumour,insulinoma c.421C>A p.R141S 17:7673803-7673803 18
20 COSM145036443 TP53 pancreas,NS,carcinoid-endocrine tumour,insulinoma c.700C>A p.R234S 17:7673803-7673803 18
21 COSM144672354 TP53 pancreas,NS,carcinoid-endocrine tumour,insulinoma c.700C>A p.R234S 17:7673803-7673803 18
22 COSM143391770 TP53 pancreas,NS,carcinoid-endocrine tumour,insulinoma c.700C>A p.R234S 17:7673803-7673803 18
23 COSM142580266 TP53 pancreas,NS,carcinoid-endocrine tumour,insulinoma c.700C>A p.R234S 17:7673803-7673803 18
24 COSM112274404 TP53 pancreas,NS,carcinoid-endocrine tumour,insulinoma c.817C>A p.R273S 17:7673803-7673803 18
25 COSM87922154 TP53 pancreas,NS,carcinoid-endocrine tumour,insulinoma c.817C>A p.R273S 17:7673803-7673803 18
26 COSM122291078 TP53 pancreas,NS,carcinoid-endocrine tumour,insulinoma c.421C>A p.R141S 17:7673803-7673803 18
27 COSM106072773 TP53 pancreas,NS,carcinoid-endocrine tumour,insulinoma c.817C>A p.R273S 17:7673803-7673803 18
28 COSM143173580 TP53 pancreas,NS,carcinoid-endocrine tumour,insulinoma c.340C>A p.R114S 17:7673803-7673803 18
29 COSM143961788 TP53 pancreas,NS,carcinoid-endocrine tumour,insulinoma c.340C>A p.R114S 17:7673803-7673803 18
30 COSM99578838 MEN1 pancreas,NS,carcinoid-endocrine tumour,gastrinoma c.422A>G p.Q141R 11:64809688-64809688 18
31 COSM100255014 MEN1 pancreas,NS,carcinoid-endocrine tumour,glucagonoma c.266T>G p.L89R 11:64809844-64809844 18
32 COSM92075551 MEN1 pancreas,NS,carcinoid-endocrine tumour,gastrinoma c.422A>G p.Q141R 11:64809688-64809688 18
33 COSM100204359 MEN1 pancreas,NS,carcinoid-endocrine tumour,gastrinoma c.654+2T>A p.? 11:64807889-64807889 18
34 COSM100206870 MEN1 pancreas,NS,carcinoid-endocrine tumour,gastrinoma c.422A>G p.Q141R 11:64809688-64809688 18
35 COSM99564038 MEN1 pancreas,NS,carcinoid-endocrine tumour,gastrinoma c.376T>G p.W126G 11:64809734-64809734 18
36 COSM90430055 MEN1 pancreas,NS,carcinoid-endocrine tumour,gastrinoma c.654+2T>A p.? 11:64807889-64807889 18
37 COSM92200043 MEN1 pancreas,NS,carcinoid-endocrine tumour,glucagonoma c.266T>G p.L89R 11:64809844-64809844 18
38 COSM100180429 MEN1 pancreas,NS,carcinoid-endocrine tumour,gastrinoma c.1004G>C p.R335P 11:64806292-64806292 18
39 COSM99563345 MEN1 pancreas,NS,carcinoid-endocrine tumour,glucagonoma c.266T>G p.L89R 11:64809844-64809844 18
40 COSM99581318 MEN1 pancreas,NS,carcinoid-endocrine tumour,gastrinoma c.1004G>C p.R335P 11:64806292-64806292 18
41 COSM100244962 MEN1 pancreas,NS,carcinoid-endocrine tumour,glucagonoma c.536A>T p.E179V 11:64808009-64808009 18
42 COSM92200548 MEN1 pancreas,NS,carcinoid-endocrine tumour,gastrinoma c.376T>G p.W126G 11:64809734-64809734 18
43 COSM99575408 MEN1 pancreas,NS,carcinoid-endocrine tumour,glucagonoma c.266T>G p.L89R 11:64809844-64809844 18
44 COSM100249817 MEN1 pancreas,NS,carcinoid-endocrine tumour,gastrinoma c.884G>C p.R295P 11:64806292-64806292 18
45 COSM100203843 MEN1 pancreas,NS,carcinoid-endocrine tumour,glucagonoma c.266T>G p.L89R 11:64809844-64809844 18
46 COSM100244409 MEN1 pancreas,NS,carcinoid-endocrine tumour,gastrinoma c.376T>G p.W126G 11:64809734-64809734 18
47 COSM99576000 MEN1 pancreas,NS,carcinoid-endocrine tumour,gastrinoma c.669+2T>A p.? 11:64807889-64807889 18
48 COSM90435584 MEN1 pancreas,NS,carcinoid-endocrine tumour,gastrinoma c.989G>C p.R330P 11:64806292-64806292 18
49 COSM100174570 MEN1 pancreas,NS,carcinoid-endocrine tumour,glucagonoma c.551A>T p.E184V 11:64808009-64808009 18
50 COSM99569940 MEN1 pancreas,NS,carcinoid-endocrine tumour,gastrinoma c.1004G>C p.R335P 11:64806292-64806292 18

Copy number variations for Islet Cell Tumor from CNVD:

6 (show all 16)
# CNVD ID Chromosome Start End Type Gene Symbol CNVD Disease
1 36717 1 79269825 120225489 Loss PSRC1 Pancreatic endocrine tumor
2 38231 10 1 77700000 Gain RET Pancreatic endocrine tumor
3 40010 10 123100000 127500000 Loss DMBT1 Pancreatic endocrine tumor
4 45931 10 75266020 135228726 Loss PTEN Pancreatic endocrine tumor
5 49582 11 108093559 108239826 Loss ATM Pancreatic endocrine tumor
6 49994 11 112500000 114500000 Loss PPP2R1B Pancreatic endocrine tumor
7 117037 17 70900000 81195210 Loss FAS Pancreatic endocrine tumor
8 151222 20 18623480 62342703 Gain BCAS1 Pancreatic endocrine tumor
9 162982 22 23484416 48053047 Loss CHEK2 Pancreatic endocrine tumor
10 166156 3 1 91700000 Indels Pancreatic endocrine tumor
11 176562 3 49525778 51884070 Loss IFRD2 Pancreatic endocrine tumor
12 179191 3 8700000 16400000 Loss FANCD2 Endocrine pancreatic tumor
13 191665 5 1 46100000 Gain TERT Pancreatic endocrine tumor
14 206334 6 139000000 149000000 Loss Endocrine pancreatic tumor
15 225336 7 45020224 55392724 Gain EGFR Pancreatic endocrine tumor
16 236915 8 18983547 53650298 Loss BNIP3L Pancreatic endocrine tumor

Expression for Islet Cell Tumor

Search GEO for disease gene expression data for Islet Cell Tumor.

Pathways for Islet Cell Tumor

GO Terms for Islet Cell Tumor

Cellular components related to Islet Cell Tumor according to GeneCards Suite gene sharing:

# Name GO ID Score Top Affiliating Genes
1 extracellular region GO:0005576 10.07 CALCA CHGA GAST GCG IAPP IGF2
2 secretory granule lumen GO:0034774 9.86 SERPINA3 PCSK1 INS GCG
3 extracellular space GO:0005615 9.74 SST SERPINA3 SCT PTHLH PPY PCSK1
4 neuronal dense core vesicle GO:0098992 9.46 SST CHGA CALCA

Biological processes related to Islet Cell Tumor according to GeneCards Suite gene sharing:

# Name GO ID Score Top Affiliating Genes
1 positive regulation of protein kinase B signaling GO:0051897 9.86 RET INS IGF2 IAPP
2 adenylate cyclase-activating G protein-coupled receptor signaling pathway GO:0007189 9.65 VIP PTHLH IAPP GCG CALCA
3 feeding behavior GO:0007631 9.63 PPY GCG CALCA
4 amylin receptor signaling pathway GO:0097647 9.5 IAPP CALCA
5 cell-cell signaling GO:0007267 9.36 SST PTHLH PCSK1 INS IAPP CALCA

Molecular functions related to Islet Cell Tumor according to GeneCards Suite gene sharing:

# Name GO ID Score Top Affiliating Genes
1 hormone activity GO:0005179 9.66 VIP SST SCT PTHLH PPY INS

Sources for Islet Cell Tumor

2 CDC
6 CNVD
8 Cosmic
9 dbSNP
10 DGIdb
16 EFO
17 ExPASy
18 FMA
19 GARD
27 GO
28 GTR
29 HMDB
30 HPO
31 ICD10
32 ICD10 via Orphanet
33 ICD11
34 ICD9CM
35 IUPHAR
36 LifeMap
38 LOVD
40 MedGen
43 MeSH
44 MESH via Orphanet
45 MGI
48 NCI
49 NCIt
50 NDF-RT
52 NINDS
53 Novoseek
55 ODiseA
56 OMIM via Orphanet
57 OMIM® (Updated 24-Oct-2022)
61 PubChem
62 PubMed
64 QIAGEN
69 SNOMED-CT via HPO
70 Tocris
71 UMLS
72 UMLS via Orphanet
Content
Loading form....